|Videos|July 12, 2016

What Should Healthcare Providers Consider When Prescribing Drug Therapies?

Elizabeth Dodds-Ashley, PharmD, MHS, at the Department of Medicine at Duke University School of Medicine, discusses key points to consider when deciding what drug dosage to prescribe to a patient.

Elizabeth Dodds-Ashley, PharmD, MHS, at the Department of Medicine at Duke University School of Medicine, discusses key points to consider when deciding what drug dosage to prescribe to a patient.

Interview Transcript (slightly modified for readability)

“I think [that] for front-line providers, [at] the time of writing [a] prescription, there are several important things to consider. What is the renal function or the liver function [of] the drug that we are giving to this patient? What is the best drug [for] this patient that is going to minimize toxicities (if that is possible)?

Also, [it is important] to be sure that we’re dosing [the drug] in a way that will maximize effectiveness. For some drugs that is giving more frequent doses [rather] than lumping a whole dose together once a day. For others, we can optimize [bacterial] killing by giving drugs less frequently in higher doses and giving [the patient] drug-free intervals to minimize [drug] toxicity.

Having an understanding of the drugs you use and how they work is the best way that we can [ensure] that patients are getting the right doses for all of their individual circumstances. There really is no ‘one size fits all’ antibiotic dose for our patients.”


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.